Hematologic Oncology

Dr. James Berenson from the Institute for Myeloma and Bone Cancer Research Discusses the Proteasome Inhibitor Carfilzomib

Dr. Volker Diehl from the University of Cologne, Germany on the Unique Nature of Hodgkin's Lymphoma

It’s no surprise that you acquire significant debt during your medical training. Here are some ways to get those loans paid off.

Burnout is a recurring problem for overworked oncologists and hematologists. This article includes ideas to keep you healthy, engaged, and empathic.

Ideally, all patients should receive the same oncology care, regardless of their ability to pay. The reality is often different, as this fellow can attest.

Obtaining a high-quality bone marrow aspirate and biopsy is very important for the patient—and for you. Following these general guidelines will help you do this successfully.

All fellows will at some point in their careers be required to speak in public. This article provides a number of tips to make that task easier.

A look at the benefits of the chemoimmunotherapy rituximab for CLL and a look at the treatments and advances made in treating metastatic CRC.

Dr. Pramod Mistry from Yale University School of Medicine on Gaucher Disease Entering a New Era

Dr. Gregory A. Grabowski from Cincinnati Children's Hospital Medical Center Explains the Effects of Enzyme Therapy

Dr. Rogerio Vivaldi the President of Genzyme Corporation on the Transformation of Gaucher Disease

Dr. Pramod Mistry from the Yale University School of Medicine Explains the History of Gaucher Disease

Dr. Richard Moscicki from Chief Medical Officer, Genzyme Corporation, on His Experience With Lysosomal Diseases

This month's collection of trials in progress highlights trials presented at the 2011 American Society of Clinical Meeting.

Dr. Andre Goy from John Theurer Cancer Center Highlights Recent Advances in Oncology

Myelodysplastic syndromes (MDS) are a group of hematological conditions affecting the blood stem cells in the bone marrow.

Dr. Andre Goy from John Theurer Cancer Center on Integrating Novel Therapies Into the JTCC Conference

Dr. Andre Goy from John Theurer Cancer Center on the Upcoming Conference at John Theurer Cancer Center

In 2001, Doug Rickert, a 46-year-old industrial management consultant and married father of 3, heard the life-altering words, "softball-sized tumor pressing against your spinal canal."

Through the success of Revlimid and other drugs, Celgene has become a respected and powerful player in the biopharmaceutical industry in recent years.

Brentuximab vedotin showed very positive results in lymphoma patients in several early trials, prompting the FDA's Oncologic Drugs Advisory Committee to unanimously recommend accelerated approval for the drug.

You'd never know that Rogers has had multiple myeloma for almost 11 years -- and that's just the way he likes it.

The following is a roundup of TPS abstracts that feature trials open to patients aged >17 years with a broad range of cancer types.

Progress in our understanding of multiple myeloma pathogenesis has led to the identification of new therapeutic targets.

The FDA announced that brentuximab vedotin has been approved for the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.